Skip to ContentSkip to Navigation
Practical matters How to find us drs. M. Nijland

Publications

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma: a population-based analysis

Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome

Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [F-18]FDG PET/CT features

Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma

Read more

Press/media

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

Medtalks:Diffuus Grootcellig B-cellymfoom 2018